Barrington Research Maintains Outperform on Concentrix, Lowers Price Target to $30

Benzinga Newsdesk www.benzinga.com Negative 95.6%

Neg 95.6% Neu 0% Pos 0%

Barrington Research analyst Vincent Colicchio maintains Concentrix (NASDAQ:CNXC) with a Outperform and lowers the price target from $38 to $30.